EDP-938: Clinical Trials

4 trials of EDP-938, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 3, Terminated 1

Follow EDP-938: new trials by email Literature Review of EDP-938 trials Research Report on EDP-938

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
EDP-938, Placebo - RSV Infection
Phase 2CompletedEnanta Pharmaceuticals, Inc1872022-11-292026-08-19
A Study to Evaluate EDP 938 Regimens in Children With RSV
EDP-938, Placebo - Respiratory Syncytial Virus (RSV)
Phase 2CompletedEnanta Pharmaceuticals, Inc992022-04-262025-07-28
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
EDP-938, Placebo - Respiratory Syncytial Virus Infections
Phase 2TerminatedEnanta Pharmaceuticals, Inc92021-07-072024-08-22
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
EDP-938, Placebo - Respiratory Syncytial Virus
Phase 2CompletedEnanta Pharmaceuticals, Inc822020-01-222023-10-30

Conditions studied

Respiratory Syncytial Virus Infections (2)

Sponsors

Enanta Pharmaceuticals, Inc (4)

Countries

Argentina (4)  ·  Poland (4)  ·  South Africa (4)  ·  United States (4)  ·  Mexico (3)  ·  Spain (3)  ·  Taiwan (3)  ·  Brazil (2)  ·  Bulgaria (2)  ·  Colombia (2)  ·  Israel (2)  ·  New Zealand (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Australia (1)

Top investigators

Scott Rottinghaus, MD (1)